Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Invested Capital: 2010-2025

Historic Invested Capital for Sunshine Biopharma (SBFM) over the last 11 years, with Sep 2025 value amounting to $24.2 million.

  • Sunshine Biopharma's Invested Capital fell 3.35% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 3.35%. This contributed to the annual value of $23.5 million for FY2024, which is 10.81% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Invested Capital of $24.2 million as of Q3 2025, which was down 5.78% from $25.7 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Invested Capital peaked at $41.9 million during Q2 2022, and registered a low of -$1.2 million during Q3 2021.
  • Over the past 3 years, Sunshine Biopharma's median Invested Capital value was $23.5 million (recorded in 2024), while the average stood at $23.2 million.
  • Its Invested Capital has fluctuated over the past 5 years, first spiked by 10,117.97% in 2022, then plummeted by 45.61% in 2023.
  • Sunshine Biopharma's Invested Capital (Quarterly) stood at $211,662 in 2021, then spiked by 10,117.97% to $21.6 million in 2022, then fell by 1.94% to $21.2 million in 2023, then climbed by 10.81% to $23.5 million in 2024, then declined by 3.35% to $24.2 million in 2025.
  • Its Invested Capital was $24.2 million in Q3 2025, compared to $25.7 million in Q2 2025 and $22.7 million in Q1 2025.